Aclaris Therapeutics (ACRS) Enterprise Value (2014 - 2026)

Aclaris Therapeutics' Enterprise Value history runs 13 years deep, the most recent figure standing at -$105.4 million for Q1 2026.

• In Q1 2026, Enterprise Value changed 0.1% year-over-year to -$105.4 million; the TTM figure through Mar 2026 stood at -$105.4 million (changed 0.1% YoY), while the FY2025 annual figure was -$90.8 million, up 20.11% from the prior year.
• Enterprise Value was -$105.4 million for Q1 2026 at Aclaris Therapeutics, down from -$90.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$90.8 million in Q4 2025 to a low of -$248.6 million in Q2 2022.
• Historically, Enterprise Value has averaged -$140.3 million across 5 years, with a median of -$119.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value slumped 40.01% in 2022, then surged 58.46% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$217.6 million in 2022, then surged by 45.26% to -$119.1 million in 2023, then grew by 4.63% to -$113.6 million in 2024, then increased by 20.11% to -$90.8 million in 2025, then decreased by 16.16% to -$105.4 million in 2026.
• The last three Enterprise Value figures came in at -$105.4 million (Q1 2026), -$90.8 million (Q4 2025), and -$95.9 million (Q3 2025), per Business Quant data.